Viva Biotech Holdings is a pharmaceutical company based in China with an ESG score of 25.0, reflecting a medium risk level. Specializing in drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services, the company generates revenue through manufacturing, trading, and development of small molecule APIs and intermediates. Viva Biotech Holdings operates globally, with a focus on the United States, European Union, Chinese Mainland, Africa, and other regions.